Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.50 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21059515 | 1.00 | PTGDR2 (0.50) | PTGDR2PTGDRKMT2ATSHRHTR2A | |
| SCHEMBL21059483 | 0.85 | PTGDR2 (0.62) | PTGDR2PTGDRKMT2ATSHRHTR2A | |
| SCHEMBL21059486 | 0.85 | PTGDR2 (0.62) | PTGDR2PTGDRKMT2ATSHRHTR2A | |
| SCHEMBL21059447 | 0.83 | PTGDR2 (0.67) | PTGDR2PTGDRKMT2ATSHRHTR2A | |
| SCHEMBL21059445 | 0.83 | PTGDR2 (0.67) | PTGDR2PTGDRKMT2ATSHRHTR2A | |
| SCHEMBL28444725 | 0.82 | PTGDR2 (0.65) | PTGDR2PTGDRKMT2ATSHRHTR2A | |
| SCHEMBL28444727 | 0.82 | PTGDR2 (0.65) | PTGDR2PTGDRKMT2ATSHRHTR2A | |
| SCHEMBL21057192 | 0.78 | PTGDR2 (0.51) | PTGDR2PTGDRKMT2ATSHRHTR2A | |
| SCHEMBL21057194 | 0.78 | PTGDR2 (0.51) | PTGDR2PTGDRKMT2ATSHRHTR2A | |
| SCHEMBL21059519 | 0.77 | PTGDR2 (0.44) | PTGDR2PTGDRKMT2ATSHRHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3723746-B1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2022-02-23 | — | — | EP | claimed |
| US-20190185409-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS (DK) | 2019-06-20 | — | — | US | claimed |
| US-20190183812-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | claimed |
| US-11591284-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-02-28 | — | — | US | disclosed |
| EP-3723746-B1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2022-02-23 | — | — | EP | disclosed |
| US-20190183812-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190185409-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS (DK) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185409-A1 | Compounds For The Treatment Of Neuromuscular Disorders | CPT1B, CLCN2, CACNB1 | PTGDR2 1344/4885PTGDR 1130/4885KMT2A 2981/4885 |
| US-20190183812-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | PTGDR2 2581/4885PTGDR 2725/4885KMT2A 3390/4885 |
| US-11591284-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, CACNA1S | PTGDR2 1624/4885PTGDR 1550/4885KMT2A 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.